Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic, Squamous Cell, Carcinoma, Recurrent, Pepinemab, Pembrolizumab, Head, Neck, VX15/2503, Solid Tumors, Immunotherapy, Progression-Free Survival (PFS), Objective Response Rate (ORR), Duration of Response (DOR), Pharmacokinetics (PK), Pharmacodynamics (PD), Immunogenicity, Biomarkers, Overall Survival (OS), Extent of Disease (EOD), Exploratory, Biopsy, T-Cell, Myeloid Suppressor Cells, ECG, KEYTRUDA, Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Recurrence, pepinemab + pembrolizumab
Lead Scientist at UCSF
- Alain Algazi
Dr. Alain Algazi is a specialist in medical treatment – such as chemotherapy and immunotherapy – for patients with head and neck cancers, including head and neck squamous cell carcinoma, thyroid cancers and salivary gland cancers. He leads UCSF's program in medical therapy for head and neck cancers, and chairs the head and neck cancer research committee.
- accepting new patients
- Start Date
- Completion Date
- Vaccinex Inc.
- 19. Keytruda® (pembrolizumab) prescribing information (June 2020; injection for intravenous use).
- Phase 1/2 research study
- Study Type
- Expecting 65 study participants
- Last Updated